β-Hydroxybutyrate inhibits NLRP3 inflammasome, reduces Aβ internalization, and mitigates AD progression. 2-DG enhances bioenergetic capacity and promotes Aβ clearance. Here, NLRP3 is linked to Alzheimer disease.